Oral vaccination: where we are?

被引:60
作者
Silin, Dmytro S. [1 ]
Lyubomska, Oksana V. [1 ]
Jirathitikal, Vichai [1 ]
Bourinbaiat, Aldar S. [1 ]
机构
[1] Immunitor USA Inc, College Pk, MD 20740 USA
关键词
immunotherapy; mucosal vaccination; native immunity; oral tolerance; vaccine delivery;
D O I
10.1517/17425247.4.4.323
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As early as 900 years ago, the Bedouins of the Negev desert were reported to kill a rabid dog, roast its liver and feed it to a dog-bitten person for three to five days according to the size and number of bites [1]. In sixteenth century China, physicians routinely prescribed pills made from the fleas collected from sick cows, which purportedly prevented smallpox. One may dismiss the wisdom of the Bedouins or Chinese but the Nobel laureate, Charles Richet, demonstrated in 1900 that feeding raw meat can cure tuberculous dogs - an approach he termed zomotherapy. Despite historical clues indicating the feasibility of oral vaccination, this particular field is notoriously infamous for the abundance of dead-end leads. Today, most commercial vaccines are delivered by injection, which has the principal limitation that recipients do not like needles. In the last few years, there has been a sharp increase in interest in needle-free vaccine delivery; new data emerges almost daily in the literature. So far, there are very few licensed oral vaccines, but many more vaccine candidates are in development. Vaccines delivered orally have the potential to take immunization to a fundamentally new level. In this review, the authors summarize the recent progress in the area of oral vaccines.
引用
收藏
页码:323 / 340
页数:18
相关论文
共 184 条
[71]   Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant [J].
Kende, M ;
Del Giudice, G ;
Rivera, N ;
Hewetson, J .
VACCINE, 2006, 24 (12) :2213-2221
[72]   Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria [J].
Kerneis, S ;
Bogdanova, A ;
Kraehenbuhl, JP ;
Pringault, E .
SCIENCE, 1997, 277 (5328) :949-952
[73]   Liposomes and ISCOMs [J].
Kersten, GFA ;
Crommelin, DJA .
VACCINE, 2003, 21 (9-10) :915-920
[74]   Synthesis and assembly of SIVmac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato [J].
Kim, TG ;
Gruber, A ;
Ruprecht, RM ;
Langridge, WHR .
MOLECULAR BIOTECHNOLOGY, 2004, 28 (01) :33-40
[75]   Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers [J].
Kirkpatrick, BD ;
McKenzie, R ;
O'Neill, JP ;
Larsson, CJ ;
Bourgeois, AL ;
Shimko, J ;
Bentley, M ;
Makin, J ;
Chatfield, S ;
Hindle, Z ;
Fidler, C ;
Robinson, BE ;
Ventrone, CH ;
Bansal, N ;
Carpenter, CM ;
Kutzko, D ;
Hamlet, S ;
LaPointe, C ;
Taylor, DN .
VACCINE, 2006, 24 (02) :116-123
[76]   Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection [J].
Kleanthous, H ;
Myers, GA ;
Georgakopoulos, KM ;
Tibbitts, TJ ;
Ingrassia, JW ;
Gray, HL ;
Ding, R ;
Zhang, ZZ ;
Lei, WD ;
Nichols, R ;
Lee, CK ;
Ermak, TH ;
Monath, TP .
INFECTION AND IMMUNITY, 1998, 66 (06) :2879-2886
[77]   Evaluation of the Lon-deficient Salmonella strain as an oral vaccine candidate [J].
Kodama, C ;
Eguchi, M ;
Sekiya, Y ;
Yamamoto, T ;
Kikuchi, Y ;
Matsui, H .
MICROBIOLOGY AND IMMUNOLOGY, 2005, 49 (12) :1035-1045
[78]   Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant [J].
Kodama, S ;
Abe, N ;
Hirano, T ;
Suzuki, M .
LARYNGOSCOPE, 2006, 116 (02) :331-335
[79]   Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli [J].
Koprowski, H ;
Levine, MM ;
Anderson, RJ ;
Losonsky, G ;
Pizza, M ;
Barry, EM .
INFECTION AND IMMUNITY, 2000, 68 (09) :4884-4892
[80]   Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine [J].
Kotloff, KL ;
Wasserman, SS ;
Jones, KF ;
Livio, S ;
Hruby, DE ;
Franke, CA ;
Fischetti, VA .
INFECTION AND IMMUNITY, 2005, 73 (04) :2360-2366